Conclusions
1 evidence topic · 4 sources
Summary
The reported PEAK results support a progression-free-survival and response-rate benefit for bezuclastinib plus sunitinib compared with sunitinib alone after prior imatinib. Overall-survival data remained immature. The application received Priority Review, and the reported target action date was November 30, 2026. The company continued to describe GIST approval as potential rather than completed.